SOHO 2024 | The importance of measurable residual FLT3-ITD before alloSCT for AML
Christopher Hourigan
• 4 Sep 2024
Christopher Hourigan, DM, DPhil, FRCP, Virginia Tech FBRI Cancer Research Center, Washington, DC, discusses the tracking of measurable residual disease (MRD) in acute myeloid leukemia (AML) and how persistent FLT3-ITD is associated with poor outcomes. He references the Pre-MEASURE study, which investigated the impact of persistent FLT3-ITD on the outcomes of allogeneic stem cell transplantation (alloSCT). This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
